Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Theravance Biopharma R&D IP, LLC”

252 pharma patents match "Theravance Biopharma R&D IP, LLC" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 252
Index total 30,257
Page 6 / 11

Quick answer

This filtered view shows 252 pharmaceutical patents matching "Theravance Biopharma R&D IP, LLC" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

252 results for “Theravance Biopharma R&D IP, LLC” · 30,257 patents in full index Clear search

  1. US 10183942

    JAK kinase inhibitor compounds for treatment of respiratory disease

    Theravance Biopharma R&D IP, LLC · Granted Jan 22, 2019 · Expires Jan 17, 2039

    granted
  2. US 10172834

    (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

    Theravance Biopharma R&D IP, LLC · Granted Jan 8, 2019 · Expires Jan 3, 2039

    granted
  3. US 10130642

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Nov 20, 2018 · Expires Nov 15, 2038

    granted
  4. US 10123984

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Nov 13, 2018 · Expires Nov 8, 2038

    granted
  5. US 10106503

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Oct 23, 2018 · Expires Oct 18, 2038

    granted
  6. US 10100013

    Crystalline freebase forms of a biphenyl compound

    Theravance Biopharma R&D IP, LLC · Granted Oct 16, 2018 · Expires Oct 11, 2038

    granted
  7. US 10100049

    JAK kinase inhibitor compounds for treatment of respiratory disease

    Theravance Biopharma R&D IP, LLC · Granted Oct 16, 2018 · Expires Oct 11, 2038

    granted
  8. US 10100021

    Crystalline(2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof

    Theravance Biopharma R&D IP, LLC · Granted Oct 16, 2018 · Expires Oct 11, 2038

    granted
  9. US 10081626

    8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Sep 25, 2018 · Expires Sep 20, 2038

    granted
  10. US 10072026

    Crystalline form of 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

    Theravance Biopharma R&D IP, LLC · Granted Sep 11, 2018 · Expires Sep 6, 2038

    granted
  11. US 10053417

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Aug 21, 2018 · Expires Aug 16, 2038

    granted
  12. US 10034870

    4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

    Theravance Biopharma R&D IP, LLC · Granted Jul 31, 2018 · Expires Jul 26, 2038

    granted
  13. US 10028960

    Pyrimidine compounds as JAK kinase inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Jul 24, 2018 · Expires Jul 19, 2038

    granted
  14. US 10005740

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Jun 26, 2018 · Expires Jun 21, 2038

    granted
  15. US 9981999

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted May 29, 2018 · Expires May 24, 2038

    granted
  16. US 9975877

    Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists

    Theravance Biopharma R&D IP, LLC · Granted May 22, 2018 · Expires May 17, 2038

    granted
  17. US 9949963

    Crystalline forms of an 8-azabicyclo[3.2.1]octane compound

    Theravance Biopharma R&D IP, LLC · Granted Apr 24, 2018 · Expires Apr 19, 2038

    granted
  18. US 9926272

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Mar 27, 2018 · Expires Mar 22, 2038

    granted
  19. US 9884807

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  20. US 9873692

    Quinolinone-carboxamide compounds as 5-HT4 receptor agonists

    Theravance Biopharma R&D IP, LLC · Granted Jan 23, 2018 · Expires Jan 18, 2038

    granted
  21. US 9873685

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Jan 23, 2018 · Expires Jan 18, 2038

    granted
  22. US 9873696

    Neprilysin inhibitors

    Theravance Biopharma R&D IP, LLC · Granted Jan 23, 2018 · Expires Jan 18, 2038

    granted
  23. US 9872855

    (2R,4R)-5-(5′-Chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

    Theravance Biopharma R&D IP, LLC · Granted Jan 23, 2018 · Expires Jan 18, 2038

    granted
  24. US 9868698

    (2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid

    Theravance Biopharma R&D IP, LLC · Granted Jan 16, 2018 · Expires Jan 11, 2038

    granted